Ritalin should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.
Ritalin hydrochloride, methylphenidate hydrochloride USP, is a mild central nervous system (CNS) stimulant, available as tablets of 5, 10, and 20 mg for oral administration; Ritalin-SR is available as sustained-release tablets of 20 mg for oral administration.
Attention Deficit Disorders, Narcolepsy
Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.
Ritalin is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.
Special Diagnostic Considerations
Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources.
Characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, and moderate-to-severe hyperactivity; minor neurological signs and abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physicians assessment of the chronicity and severity of the childs symptoms.
Media Articles Related to Ritalin (Methylphenidate)
Scientists show cognitive enhancing drugs can improve chess play
Source: Pharma Industry / Biotech Industry News From Medical News Today [2017.03.08]
The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate (best known under the trade name Ritalin), and caffeine, on chess play is being...
Published Studies Related to Ritalin (Methylphenidate)
The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1
advanced cancer... CONCLUSION: MPH does not improve fatigue in the population of patients with
Drug-specific laterality effects on frontal lobe activation of atomoxetine and
methylphenidate in attention deficit hyperactivity disorder boys during working
CONCLUSIONS: The study shows both shared and drug-specific effects. ATX
Long-term (1 year) safety and efficacy of methylphenidate modified-release
long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity
disorder: a 26-week, flexible-dose, open-label extension to a 40-week,
double-blind, randomised, placebo-controlled core study. 
26-week, open-label extension phase of the same study (NCT01338818)... CONCLUSIONS: In adult patients with ADHD, use of MPH-LA up to 1 year continued to
Effect of extended-release dexmethylphenidate and mixed amphetamine salts on
sleep: a double-blind, randomized, crossover study in youth with
attention-deficit hyperactivity disorder. 
measures of sleep... CONCLUSIONS: Higher stimulant doses were associated with reduced sleep duration
A randomized, double-blind, placebo-controlled, parallel-group study to evaluate
the efficacy and safety of osmotic-controlled release oral delivery system
methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in
attention-deficit/hyperactivity disorder (ADHD)... CONCLUSIONS: OROS MPH in a dose range of 18-72 mg once daily was effective and
Clinical Trials Related to Ritalin (Methylphenidate)
Methylphenidate Study in Breast or Gastrointestinal Cancer Patients [Terminated]
The goal of this clinical research study is to see if the drug OROS Methylphenidate HCl
(Concerta) can help to control fatigue in patients with breast, gastrointestinal, lymphoma,
myeloma or lung cancer who are going through chemotherapy or hormonal treatment or have
completed chemotherapy or hormonal treatment in the last 12 months. The safety of this drug
will also be studied. Another goal of the study is to see how certain cytokines change
while patients undergo chemotherapy or hormonal treatment.
Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD [Completed]
Methylphenidate may improve sleep in children with ADHD. By leaving Daytrana
(methylphenidate) patch for a longer time then 9 hours, many children report short sleep
latencies and better quality of sleep.
The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. [Terminated]
This project aims to determine if methylphenidate can improve deficits in attention and
symptoms of orthostatic hypotension, two common non-motor symptoms, in patients with
Parkinson's Disease. This project also seeks to evaluate the effect of methylphenidate on
postural control in these patients, a debilitating motor symptom that places patients at an
increased risk of falling. This study will build on existing data to support a new
indication for the use of methylphenidate in Parkinson's Disease. Using standard and
objective evaluations, this study will quantify the effect of methylphenidate at two doses
on attention levels, orthostatic hypotension, and measures of postural control. Phase I of
the study will compare methylphenidate 10mg three times daily to placebo and Phase II of the
study, for those tolerating the lower dose in Phase I, will compare methylphenidate 20mg
three times daily to placebo. By incorporating two different doses, the study also seeks to
determine if any improvements are dose-related. Secondary endpoints will include safety
assessments (adverse event monitoring and vital signs) performed every 30 minutes following
supervised drug administration. Visual analog scales will be presented to each participant
before treatment and following the final dose of each treatment to assess changes in
fatigue. A secondary task will be added to postural tests to assess the influence of
cognitive processes. It is hypothesized that methylphenidate will demonstrate a significant
beneficial effect on all outcomes. It is projected that objective improvements will be
observed following treatment with methylphenidate at both doses (10 and 20mg three time
daily) when compared to placebo. It is further hypothesized that the effects will be
dose-related and therefore more profound with higher doses.
A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers [Completed]
Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study [Recruiting]
Traditionally, memory impairments in the elderly population are treated using cholinesterase
inhibitors, although impairments remain after treatment. Dopamine (DA) is also involved in
cognition and is especially of interest in healthy ageing because of the role in processing
speed and cognitive control. To what extent dopamine treatment improves memory and attention
in older impaired individuals is unknown. However, such an effect is conceivable because of
the close relationship between memory and attention in aging and since improved processing
speed and cognitive control may lead to improved memory.
The investigators aim to examine, in the impaired older population, whether a treatment
using methylphenidate, a DA re-uptake inhibitor that enhances DA, improves attention and
memory. The study will be conducted according to a cross-sectional, double-blind,
placebo-controlled, 2-way cross-over design. 20 male and female patients with Mild Cognitive
Impairment (MCI), amnestic type, aged above 60 years of age; 20 male and female patients
with MCI, non-amnestic type, will be recruited from the Orbis Medical Centre. Participants
will be treated once with 20 mg methylphenidate (MPH) and once with placebo. All medications
will be administered orally with a capsule. The treatment order will be established by
Reports of Suspected Ritalin (Methylphenidate) Side Effects
Drug Ineffective (30),
Suicidal Ideation (20),
Attention Deficit/hyperactivity Disorder (20),
Disturbance in Attention (19),
Tremor (17), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 11 ratings/reviews, Ritalin has an overall score of 8.09. The effectiveness score is 8.55 and the side effect score is 7.82. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Ritalin review by 59 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || fibromyalgia|
|Dosage & duration:|| || 10 mg taken 3 times a day for the period of 10+ years|
|Other conditions:|| || migraine, ibs, dry eye syndrome|
|Other drugs taken:|| || synthroid, norvasc|
|Benefits:|| || was placed on ritalin due to extreme fatigue assosicated with fibromyalgia.
medication highly effective in overcoming lack of energy and the tiredness that would never seem to go away.
the fatigue was worse than the physical pain associated with fibromyalgia.|
|Side effects:|| || well tolerated--none|
|Comments:|| || i take 15 mgs in am and noon and 10 mg late afternoon.
this medication has given me a life back and am forever grateful to be on it.
this medication sometimes gets a bad rap and does not appear to be used widely for the treatment of fibromyalgia, but for me it is a true, true positive medication with no side effects.|
Ritalin review by 28 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || ADD|
|Dosage & duration:|| || 20mg taken twice a day for the period of 2 months|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || While i take this drug, i feel very well, happy, I can concentrate in my activities. It helps me to make decisions, I can complete activities, i talk a lot, i stay in a good mood, but just while is during the effects. |
|Side effects:|| || My heart beats faster and i feel its not in a constant rhythm. My mouth is dry and I feel extremely anxious, and because of this, very clumsy. |
|Comments:|| || My diagnostic of ADD was not really accurate. A did just some practical test but no brain exam. The doctor prescribe ritalin as a test, but because of the side effects I had to stop. I did psychotherapy during the treatment. The ritalin helped me but,of course, didn't stop my problems. I feel really better now, but i didn't find yet a drug to help instead of ritalin.|
Ritalin review by 48 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Moderately Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || depression|
|Dosage & duration:|| || 20 mg/day taken daily for the period of began six months ago|
|Other conditions:|| || cancer, high cholesterol|
|Other drugs taken:|| || Tamoxifen, Cymbalta, Zyprexa, Lipitor, Valtrex, Cilicaine VX|
|Benefits:|| || When I first began taking the Ritalin, I noticed a dramatic effect on my mood. I felt wonderful! I was energetic and positive and I felt that I could handle anything that came my way. I don't want to sound as though I felt euphoric or manic - I just felt really GOOD about life. However, after only a few days, that sense of confident well-being drained away.|
|Side effects:|| || Initially, the medication kept me awake all night but that only happened for a night or two. I take them on an empty stomach in the morning and sometimes my hands shake very slightly for a while but it's not enough to cause any problems.|
|Comments:|| || My psychiatrist put me on it to 'give a boost' to my other antidepressant. He says I am taking a miniscule amount, and that I could increase the dosage if I wished but I have been reluctant to do so. Perhaps I should - I may not be taking enough to be effective but I am on three different antidepressants and I feel uneasy about sharply increasing the Ritalin dose. In short, initially, I felt GREAT but now I feel just the same as ever - struggling with the thoughts that cause lack of energy & enjoyment in many spheres of life.|
Page last updated: 2017-03-08